timothy sykes logo
Braskem Stock Declines Amid Financial Struggles and Analyst Downgrades Thumbnail
ADD US ONG Google News

Braskem Stock Declines Amid Financial Struggles and Analyst Downgrades

TIM SYKES•UPDATED MAR. 29, 2026, 10:05 AM ET
Reviewed by Jack Kellogg Fact-checked by Ellis Hobbs

Braskem SA ADR stocks have been trading down by -10.66 percent amid market volatility and economic pressures.

  • Braskem’s Q4 financial results reveal a massive net loss of 10.28 billion reais. This substantial downturn reflects in its gross revenue decline, causing the stock to plunge roughly 6% in premarket trading.

  • Additionally, there is significant uncertainty regarding Braskem’s ability to continue as a going concern. This uncertainty stems from the sharp net loss and revenue drop noted in the recent financial report, leading to a severe decline in stock price.

Candlestick Chart

Weekly Update Mar 23 – Mar 27, 2026: On Sunday, March 29, 2026 Braskem SA ADR stock [NYSE: BAK] is trending down by -10.66%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Materials industry expert:

Analyst sentiment – negative

Braskem (BAK) finds itself in a precarious financial position. Key fundamentals reveal troubling metrics, including a negative book value per share of -10.59 and a price-to-tangible book of -0.8, suggesting significant asset impairment or depreciation. The company’s leverage ratio is distressingly high, reflected in a long-term debt and capital lease obligation nearing 67 billion. Revenue stood at 77 billion, but with a negative revenue growth over three and five years, the company struggles with sustained revenue generation. With a pretax profit margin at 5.3, Braskem fails to convert sales into meaningful profit, casting doubt on its future financial prospects.

Technical analysis of Braskem’s recent price data indicates a bearish trend. Daily price action shows sustained downward pressure, closing at 3.52 – a significant fall from earlier highs of 4.25. This price trajectory aligns with volume peaks predominantly tied to downward candles, signaling strong sell-side sentiment. Current price action suggests downside momentum, with resistance at the recent high of 4.25 and support likely forming near 3.50. Traders might consider short positions at retracements toward 4.00, with stop losses above 4.25, capitalizing on the downtrend continuation.

Recent developments further challenge Braskem. Bank of America downgraded the stock to underperform, citing cash burn and impending debt maturity of $383M, threatening liquidity. The company’s Q4 report reveals a stark net loss of 10.28 billion reais, with a sharp revenue drop. Compared to its industry benchmarks, Braskem significantly underperforms, signaling systemic issues. Despite the potential for short-term corrective rallies, the overall outlook remains bleak with looming support at 2.80 as suggested by recent analyst downgrades. Given these factors, the company’s prospects are decidedly negative.

Quick Financial Overview

The recent financial performance of Braskem shows troubling signs. In Q4, the company recorded a net loss of 10.28 billion reais. This is a stark contrast to its revenue, which dropped massively from 22.44 billion reais to 18.30 billion reais. The stock responded negatively, dropping by about 6% in premarket activity. These results suggest declining operational efficiency and financial viability. The company’s key financial ratios paint a picture of a beleaguered entity. Its pretax profit margin stands at a mere 5.3%. With a price-to-sales ratio of 0.12, investors are seemingly paying less per revenue unit, indicating diminished confidence in growth.

Braskem’s financial strength indicators further illustrate distress. Total debt to long-term capital is at 1.07, implying a high debt burden as a proportion of its capital structure. Furthermore, the company’s enterprise value of $12,445.77M, juxtaposed against falling revenues and widening losses, raises concerns among investors and analysts. As for its stocks, over the past few trading days, there was a downward trend with prices commencing at $4.25 and eventually dropping to $3.52. This decline aligns with the recent unfavorable financial news, indicating investor sentiment that reflects caution and might adjust to credit ratings and operational feasibility.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading BAK

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”